Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease

Plain-language summary

This study provides long-term follow-up of participants with APOE4 homozygote Alzheimer's disease who previously received the gene therapy LX1001 in an earlier study (LX1001-01). Only participants who had already received LX1001 are included. The study is in Phase 1 and is currently active but not recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Active, not recruiting

Sponsor

Lexeo Therapeutics

Intervention

LX1001

Start date

5/8/2023

Estimated completion

11/1/2028

Countries

United States

Related genes

Locations

• Orlando, United States
• Durham, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Participants who received LX1001 in study LX1001-01

Exclusion Criteria:

* Participants with any clinically significant medical condition that, in the opinion of the investigator, would pose a risk to participant safety
* Participants who agree not to post their personal medical data in relation to this study or any study information online, including social media sites, until all participants have completed all LX1001 clinical studies, including long-term follow-up.